Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1967 1
1968 2
1969 1
1970 1
1971 3
1972 1
1973 1
1974 4
1975 4
1976 1
1977 2
1983 3
1984 2
1985 6
1986 4
1987 1
1988 2
1990 1
1991 6
1992 2
1993 2
1994 7
1995 6
1996 3
1997 1
1998 2
1999 4
2000 2
2001 4
2003 4
2004 5
2005 3
2006 3
2007 3
2008 4
2009 5
2010 6
2011 8
2012 5
2013 5
2014 4
2015 7
2016 5
2017 6
2018 10
2019 4
2020 8
2021 12
2022 10
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Turner NC, et al. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. N Engl J Med. 2015. PMID: 26030518 Free article. Clinical Trial.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: hara f. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
[Fibrates].
Hara F, Yamazaki J. Hara F, et al. Nihon Rinsho. 2013 Sep;71(9):1643-8. Nihon Rinsho. 2013. PMID: 24205728 Review. Japanese.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T. Terada M, et al. Among authors: hara f. Breast Cancer. 2023 Nov;30(6):872-884. doi: 10.1007/s12282-023-01505-x. Epub 2023 Oct 7. Breast Cancer. 2023. PMID: 37804479 Free PMC article.
Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.
Saeki S, Iwatani T, Kitano A, Sakurai N, Tanabe Y, Yamauchi C, Igarashi A, Kajimoto Y, Kuba S, Hara F, Sagara Y, Ohno S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Saeki S, et al. Among authors: hara f. Breast Cancer. 2023 Sep;30(5):820-830. doi: 10.1007/s12282-023-01476-z. Epub 2023 Jun 13. Breast Cancer. 2023. PMID: 37310584 Free PMC article.
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
Sasada S, Kondo N, Hashimoto H, Takahashi Y, Terata K, Kida K, Sagara Y, Ueno T, Anan K, Suto A, Kanbayashi C, Takahashi M, Nakamura R, Ishiba T, Tsuneizumi M, Nishimura S, Naito Y, Hara F, Shien T, Iwata H. Sasada S, et al. Among authors: hara f. Breast Cancer Res Treat. 2023 Dec;202(3):473-483. doi: 10.1007/s10549-023-07097-6. Epub 2023 Sep 9. Breast Cancer Res Treat. 2023. PMID: 37688665 Free PMC article.
Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
Nonomiya Y, Nakayama I, Kobayashi K, Amakawa Y, Shibata N, Soejima A, Kawakami K, Shimizu H, Takahari D, Kawai S, Hara F, Takano T, Yamaguchi K, Yamaguchi M. Nonomiya Y, et al. Among authors: hara f. Biol Pharm Bull. 2024;47(2):411-416. doi: 10.1248/bpb.b23-00695. Biol Pharm Bull. 2024. PMID: 38346748 Free article. Review.
194 results